Drug Trial Radar · NCT06984094
Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
612
Actual
Start
Jun 18, 2025
Primary completion
Mar 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Clover Biopharmaceuticals AUS PtyIndustry
- Sponsor type
- Industry
- First posted
- May 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Parts 1 and 2) or Placebo (Part 3).
Conditions
- RSV Infection
- Human Metapneumovirus Infection
- Parainfluenza Infection
Interventions
SCB-1019TBiological
SCB-1019T (bivalent recombinant RSV vaccine candidate) consists of two recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)) and RSV B strain (SCB-1019T(B)).
SCB-1022Biological
SCB-1022 (combination recombinant RSV-hMPV vaccine candidate) consists of three recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), and hMPV (SCB-1021).
SCB-1033Biological
SCB-1033 (combination recombinant RSV-hMPV-PIV3 vaccine candidate) consists of four recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), hMPV (SCB-1021) and PIV3 (SCB-1020).
Placebo (saline)Biological
0.9% saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and reactogenicity of SCB-1022 and SCB 1033 compared to SCB-1019T (Part 1 and Part 2) or Placebo (Part 3).Time frame: Within 7 days after vaccination
- To evaluate the safety and reactogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Part 1 and Part 2) or Placebo (Part 3).Time frame: Within 28 days after vaccination
- To evaluate the safety and reactogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Part 1 and Part 2) or placebo (Part 3).Time frame: Throughout the study period, from enrollment up to 2 years follow-up
- To evaluate the safety and reactogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Part 1 and Part 2).Time frame: Screening and day 8
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Fusion Clinical Research
Adelaide, Southern Australia, Australia
Paratus Clinical Research
Melbourne, Victoria, Australia
Linear Clinical Research
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.